Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis

Yang Liu, Piao-Piao Jin, Xue-Cheng Sun, Ting-Ting Hu

Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, People’s Republic of China

INTRODUCTION

Colorectal cancer (CRC) is the third most common malignancy worldwide with both prevalence and mortality increasing.[1] Diabetes mellitus (DM) is considered as an independent risk factor for CRC, with an approximately 30–40% higher risk as compared to non-DM patients.[2,3] Diabetes promotes the development of CRC carcinogenesis through complex processes. The mechanisms underlying may possibly be related to hyperinsulinemia, hyperglycemia, or an obesity-associated chronic inflammation, which may contribute to an increased cellular proliferation and tumor growth.
Several preclinical studies have demonstrated that antidiabetic medications (ADMs) may modify the risk of multiple cancers. The insulin sensitizer thiazolidinediones (TZDs), known as peroxisome proliferator-activated receptors gamma (PPAR-γ) agonists, serve as one of the ADMs options to directly reduce insulin resistance in patients with DM. PPAR-γ belongs to the nuclear hormone receptor superfamily, which forms heterodimers with retinoid X receptor to bind to DNA response elements to exert its effects. Previous studies have suggested that PPAR-γ agonists induce the differentiation and apoptosis of CRC cells, though some tumor suppression pathways, such as mTOR and LKB-1, reduce tumor growth in vitro and in vivo. In addition to antiproliferative effects in CRC, TZDs may sensitize tumor cells to anticancer therapies.

Although cancer-modifying effects are biologically plausible, data on the potential effect of TZDs are inconsistent. In earlier studies, some have shown an association between TZDs use and lower cancer risk among DM patients, while others have shown no beneficial effect.

Given the current evidence, there remains a lack of consensus regarding the effect of TZDs use on CRC risk. Thus, we performed a meta-analysis to examine the potential role of TZDs in influencing CRC susceptibility.

**PATIENTS AND METHODS**

**Study identification**

This study was performed according to the standard guidelines for meta-analyses and systematic reviews of observational studies. PubMed, EMBASE, Cochrane Library, and ISI Web of Knowledge were searched through April 2017 for observational studies investigating the association between TZDs and CRC risk, using the terms “thiazolidinediones,” “glitazones,” “troglitazone,” “pioglitazone,” “rosiglitazone,” “colorectal,” “colon,” “rectum,” “cancer,” “neoplasm,” and “risk.” The reference lists were also inspected for relevant studies.

**Study selection and quality assessment**

Eligible studies were included in the meta-analysis if they met the following criteria: (1) Full-text observational studies published in English, including cohort studies and case–control studies; (2) to compare TZDs with placebo or drugs other than TZDs; (3) with raw data on the association of TZDs use and CRC risk in DM patients, or report crude/adjusted estimates; (4) when multiple reports were published on the same population, the most recent/comprehensive publication was selected.

The quality of observational studies was assessed by Newcastle-Ottawa Scale (NOS), which included eight items scored by star. In this scale, observational studies were scored across three categories: selection of study groups, comparability of study groups, and ascertainment of the outcome of interest.

**Data extraction and synthesis**

Study selections were performed independently by two of the authors (Y Liu and PP Jin). Disagreements were resolved by consensus. The following information were extracted: First author, publication year, study duration, study location, study design, cancer site, intervention, number of patients, and cancer incidence. The strength of the associations between treatments and outcomes was estimated by relative risk (RR) and 95% confidence interval (CI). Summary estimates of the RRs were derived using fixed-effects models (Mantel–Haenszel method) or random-effects models (DerSimonian and Laird method). Adjusted estimates were pooled from the original studies if possible; otherwise, raw data were used to compute crude RRs. Heterogeneity between studies was assessed by Cochran Q-test. A P value of >0.10 for the Q-test indicated a lack of heterogeneity. I² statistic value of <30%, 30–60%, 61–75%, and >75% was suggestive of low, moderate, substantial, and considerable heterogeneity, respectively. Heterogeneity was further explored by performing meta-regression analyses using method of moments, with P < 0.10 considered statistically significant. Sensitivity analysis was performed by exclusion of each study. The presence of publication bias was assessed by Begg and Mazumdar adjusted rank correlation test (P < 0.05 indicated publication bias). The Duval and Tweedie’s trim and fill method was used for the estimation of results after correction for publication bias. All meta-analyses were performed using STATA version 12.0 (Stata Corporation, Texas).

**RESULTS**

**Eligible studies and quality assessment**

A total of 10 full-text observational studies reporting more than 18,972 CRC cases in 2,470,768 patients with DM were included in the final analysis (7 cohort studies, 3 case–control studies). Figure 1 shows the selection...
procedure. Table 1 presents the main details of the selected studies. The NOS scores for observational studies ranged from 6 to 9 stars. The overall methodological quality of evidence was high.

CRC risk in diabetic patients using TZDs
The main results of the meta-analysis are shown in Table 2. On meta-analysis of all observational studies that evaluated the risk of CRC with TZDs exposure in DM patients, the association was statistically significant (RR = 0.91, 95% CI = 0.84–0.99, P = 0.03) [Figure 2]. Considerable heterogeneity was found across studies (P heterogeneity = 0.00, I² = 82.1%). Results were unchanged in cohort studies (n = 7 studies, more than 14,278 CRC cases in 2,223,780 patients with DM; RR = 0.89, 95% CI = 0.80–0.99, P = 0.04, I² = 86.9%) [32,33,35–37]. However, such effects were not shown in case–control studies (n = 3 studies, 4,666 CRC cases in 246,988 patients with DM; RR = 0.94, 95% CI = 0.84–1.05, P = 0.28, I² = 31.9%) [37,38].

Subgroup analyses/sensitivity analyses
Subgroup analysis on study location did not show cancer-modifying effect of TZDs in Europe (n = 2 studies, more than 1,650 CRC cases in 361,722 patients with DM; RR = 0.96, 95% CI = 0.89–1.04, P = 0.34) [33,37]. A trend of protective effect was found in United States (US) (n = 7 studies, 16,971 CRC cases in 2,076,155 patients with DM; RR = 0.94, 95% CI = 0.88–1.01, P = 0.08) [23,24,32,34,36,39] although the association was not statistically significant. Only a cohort study from Asia showed a significant result (351 CRC cases in 32,891 patients with DM; RR = 0.40, 95% CI = 0.29–0.53, P = 0.00) [34]. When referred to drug type, non-pioglitazone TZD showed a modest protective effect on CRC risk in diabetic patients (n = 2 studies, 12,268 CRC cases in 1,737,613 patients with DM; RR = 0.88, 95% CI = 0.82–0.95, P = 0.00) [37,38]. However, such effect was not found in pioglitazone group (n = 3 studies, 14,969 CRC cases in 1,974,120 patients with DM; RR = 0.95, 95% CI = 0.89–1.01, P = 0.11) [33,37,38]. No significant difference was noted based on cancer site (For colon: n = 4 studies, more than 3,742 CRC cases in 660,664 patients with DM; [23,33,35,38] RR = 1.00, 95% CI = 0.99–1.02, P = 0.61. For rectum: n = 3 studies, more than 1,017 CRC cases in 598,229 patients with DM; [35,37,38] RR = 0.98, 95% CI = 0.96–1.01, P = 0.23) [Table 2].

Due to significant heterogeneity, apart from using the random-effects model, further sensitivity analysis was performed. Exclusion of any study did not considerably alter the magnitude of summary estimate [Figure 3].

The meta-regression analysis evaluating the regression of study location on log risk ratio showed significant result (Z = −2.08, P = 0.09); however, publication year (Z = 0.03,

Table 1: Main characteristics of the included studies

| First author (Year) | Study location | Study design | Cancer site | Medication | No. of cases/persons at risk | RR | 95% CI | NOS |
|---------------------|----------------|--------------|-------------|------------|-----------------------------|----|-------|-----|
| Htoo (2016)         | U.S.           | Cohort       | Colorectum  | TZD        | 167/65120                   | 0.92* | 0.68–1.26 | 9   |
| Lewis (2015)        | U.S.           | Case-control | Colon       | PIO        | 2074/236507                 | 0.91 | 0.78–1.05 | 9   |
| Sehdev (2015)       | U.S.           | Case-control | Colon       | TZD        | 1557/28046                  | 0.92 | 0.81–1.06 | 8   |
| Valent (2015)       | Italy          | Cohort       | Colon       | TZD        | n/r/109255                  | 1.00 | 0.99–1.02 | 8   |
| Lin (2014)          | Taiwan         | Cohort       | Colorectum  | TZD        | n/r/109255                  | 0.98 | 0.96–1.01 | 8   |
| Neumann (2012)      | France         | Cohort       | Colorectum  | ROSI       | 1068/1485145                | 0.97 | 0.90–1.05 | 8   |
| Ferrara (2011)      | U.S.           | Cohort       | Colon       | PIO        | 1260/252467                 | 0.90 | 0.70–1.10 | 8   |
| Oliveria (2008)     | U.S.           | Cohort       | Colorectum  | TZD        | 383/19223                   | 1.08 | 0.86–1.36 | 7   |
| Govindarajan (2007) | U.S.           | Cohort       | Colorectum  | TZD        | 1137/87687                  | 0.88 | 0.74–1.06 | 5   |
| Koro (2007)         | U.S.           | Case-control | Colon       | TZD        | 408/2435                    | 1.15 | 0.88–1.49 | 7   |

TZD: Thiazolidinedione; ROSI: Rosiglitazone; PIO: Pioglitazone; DPP-4i: dipeptidyl-peptidase-4 inhibitors; ADMs: Anti-DM drugs; NOS: Newcastle-Ottawa Scale; RR: Relative risk; CI: Confidence interval; n/r: Not reported; * RR not adjusted
Liu, et al.: Thiazolidinediones and colorectal cancer risk

Table 2: Subgroup analysis of studies comparing the association between TZDs and CRC

| Outcome                  | No. of studies | RR (95% CI) | P   | I² (%) |
|--------------------------|----------------|-------------|------|--------|
| All observational studies| 10             | 0.91 (0.84, 0.99) | 0.03 | 82.1   |
| Study design              |                |             |      |        |
| Cohort studies            | 7              | 0.89 (0.80, 0.99) | 0.04 | 86.9   |
| Case–control studies      | 3              | 0.94 (0.84, 1.05) | 0.28 | 31.9   |
| Study location            |                |             |      |        |
| Western                   | 9              | 0.96 (0.91–1.01) | 0.08 | 46.8   |
| US                        | 7              | 0.94 (0.88–1.01) | 0.08 | 0.0    |
| Europe                    | 2              | 0.96 (0.89–1.04) | 0.34 | 87.2   |
| Asia                      | 1              | 0.40 (0.29–0.53) | 0.00 | –      |
| Cancer site               |                |             |      |        |
| Colon                     | 4              | 1.00 (0.99–1.02) | 0.61 | 0.0    |
| Rectum                    | 3              | 0.98 (0.96–1.01) | 0.23 | 0.0    |
| Drug                      |                |             |      |        |
| PIO                       | 3              | 0.95 (0.89–1.01) | 0.11 | 0.0    |
| Non-PIO TZD               | 2              | 0.88 (0.82–0.95) | 0.00 | 0.0    |

RR: Relative risk; CI: confidence interval; ROSI: Rosiglitazone; PIO: Pioglitazone

Publication bias

Begg’s funnel plot was performed to assess the publication bias. The shape of the funnel plot did not reveal any evidence of asymmetry (P = 0.86) [Figure 4]. Using non-parametric Duval and Tweedie’s trim and fill method, we found no additional undisclosed trials need be performed (data not shown).

DISCUSSION

In this comprehensive meta-analysis of 10 observational studies analyzing the cancer-modifying effect of TZDs in more than two million diabetic patients, we found TZDs were associated with a modest, yet statistically significant, protective association (an estimated 9% reduction) in CRC risk compared to non-users of TZDs. The consistency of the results as shown in the sensitivity analysis and the lack of publication bias strengthened the results of this meta-analysis.

When restricting to the analysis on study population, we found the antineoplastic association of TZDs use and CRC risk was more pronounced in Asia than US (with a 60% reduction in Asia and a 6% reduction trend in US, respectively). The differences observed between the two regions should be interpreted with caution. First, different dietary habits and cultural behaviors may lead to the differential association in the two populations. Besides, a higher prevalence of central obesity is exhibited in some Asian populations, who are supposed to be more insulin resistant and more responsive to TZDs treatment as compared to Caucasians.[40-42] Moreover, only one study from Taiwan with 351 CRC cases in 32,891 DM patients was represented as an Asian population.[36] The results of other studies based on the Taiwan National Health Insurance Research Database (NHIRD) did not provide...
clear evidence of anti-CRC effect of TZDs.\textsuperscript{[22,43-45]} In view of the above-mentioned facts, more population-based studies assessing the effects of TZDs use on CRC risk in other Asian populations are needed to definitively clarify this issue.

As far as drug type is concerned, the apparent protection from malignancy conferred by non-pioglitazone TZD use (mainly rosiglitazone) was detectable in our study (a 12\% reduction in CRC risk). On the other hand, pioglitazone did not protect from malignancy. The observed discrepancies between the two types of TZDs may be due to the differences at biologic level. Pharmacologically, rosiglitazone has PPAR-\(\gamma\) activity, which has shown antiproliferative, apoptotic-inducing, and differentiation-stimulating effects in different malignancies,\textsuperscript{[10]} whereas pioglitazone has dual PPAR-\(\alpha\)-\(\gamma\) activities, which have shown carcinogenic effects in animal models, especially for bladder cancer.\textsuperscript{[46-49]} The mediation of cancer initiation and progression through various pathways may also differ between the two TZDs.\textsuperscript{[50]}

Pioglitazone continues to be recommended in current diabetes guidelines,\textsuperscript{[51]} because concerns over bladder cancer conferred by pioglitazone have largely been allayed by recent evidence.\textsuperscript{[52-54]} The side effects of rosiglitazone have limited its use, including weight gain, bone fracture, chronic edema, and heart failure.\textsuperscript{[53]} Considering the positive consequences on CRC risk, the potential implications on the risk/benefit analysis of non-pioglitazone TZDs use should be reevaluated.

We could not establish whether TZDs are differentially associated with risk of colon or rectal cancer. Comparisons that have been made for different cancer sites on CRC risk were not statistically significant.

The high statistical heterogeneity observed across studies could be partly explained by differences in study location. However, it could not be accounted for study design, cancer site, drug type, CRC cases, NOS score, or publication year. Besides, substantial heterogeneity was observed in European regions (\(I^2 = 87.2\%\)), which may lead to some degree of detection bias.

Nevertheless, generally speaking, our meta-analysis should be interpreted with caution. First, patients in the comparator group (no TZDs) received a variety of ADMs, including insulin, insulin analogs, sulfonylureas, metformin, or other hypoglycemia agents, which may have inherent cancer-modifying effects. For example, insulin or sulfonylurea has been reported to be associated with an increased risk of CRC, whereas metformin may be correlated with a decreased CRC risk.\textsuperscript{[56]} This may result in an overestimation or underestimation of the magnitude of effect on CRC. Second, all studies did not adjust for the same confounders, such as body mass index, dietary habits, or physical activity, which are all major risk factors for CRC. Besides, although many confounders can be controlled and adjusted for in the analysis, most of the included observational studies were based on retrospectively historical medical data. Thus, a complete elimination of bias on details was impossible. Third, pioglitazone and rosiglitazone are two different drugs for cancer risk. Pooling them together creates an obvious lack of drug-specific observational study. Fourth, this meta-analysis was based on published full-text articles; it may be affected by incomplete disclosure, with missing information on a lack of publication with opposite results. Fifth, this meta-analysis did not include randomized controlled trials (RCTs). Due to the small number of CRC cases and the short follow-up duration, previously published RCTs were not adequately powered to detect a significant association of TZDs use and CRC risk.\textsuperscript{[57,58]}

**CONCLUSION**

In summary, this meta-analysis indicated that the use of TZDs is associated with a significantly decreased risk of CRC. TZDs might be considered as a novel approach in cancer adjuvant therapy. Considering the observed magnitude of CRC risk reduction associated with TZDs use was relatively modest, the number needed in order to treat to prevent one case of CRC would be large. Meanwhile, careful management of individual risk/benefit profiles is needed to limit the exposure to adverse effects of TZDs use. In the future, well-designed studies with larger cohorts are warranted to confirm the potential anti-neoplastic benefit for individuals with diabetes on TZDs treatment.
Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30.
2. Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005;3:587-94.
3. Yuhara H, Steinmaus C, Cohen SE, Gorky DA, Tei Y, Buffle PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 2011;106:1911-21; quiz 22.
4. Limburg PJ, Vierkant RA, Frederiksen ZS, Leibson CI, Rizza RA, Gupta AK, et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: A population-based, retrospective cohort study. Am J Gastroenterol 2006;101:1872-9.
5. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 2005;97:1679-87.
6. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. Diabetes Care 2010;33:1674-85.
7. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr 2001;131:3109S-20S.
8. Altobelli RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: Novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53:233-56.
9. Li JY, Yu T, Xia ZS, Chen GC, Yuan YH, Zhong W, et al. Enhanced proliferation in colorectal epithelium of patients with type 2 diabetes correlates with beta-catenin accumulation. J Diabetes Complications 2014;28:689-97.
10. Shaifei-Iramnejad V, Samadi N, Salehi R, Yousefi B, Zarghami N. New Insights into Antidiabetic Drugs: Possible Applications in Cancer Treatment. Chem Biol Drug Design 2017;90:1056-66.
11. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nature Med 1998;4:1046-52.
12. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carecinogenesis 1998;19:49-53.
13. Burton JD, Goldenberg DM, Blumenthal RD. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008;2008:49161.
14. Belfiore A, Genua M, Malaguarnera R. PPAR-gamma agonists and their effects on IGF-I receptor signaling: Implications for cancer. PPAR Res 2009;2009:830501.
15. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004;5:419-29.
16. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-7.
17. Omura T. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol 2010;45:1097-102.
18. Panigrahi D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EF, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Investig 2002;110:923-32.
19. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-4.
20. Chia SJ, Hsiao CH, Tseng HH, Su YH, Shih WL, Lee JW, et al. Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells. Biochem Biophys Res Commun 2010;394:774-9.
21. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012;55:1462-72.
22. Chen SW, Tsan YT, Chen JD, Hsieh HI, Lee CH, Lin HH, et al. Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: A nationwide, population-based, case-control study. Diabetes Care 2013;36:3679-95.
23. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007;16:485-92.
24. Govindarajan R, Rattanasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007;25:1476-81.
25. Staquet MJ, Dokuso EM, Center SA, Landsittel D, Begg CB. New guideline for meta-analysis of cancer drug trials. J Clin Oncol 2008;26:603-5.
26. De’Sermonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:567-70.
28. Clarys PP, Van Geel N, Lipsky SE, van der Heijden GJ. Updated review of the anti-tumor effects of thiazolidinediones. Curr Opin Pharmacol 2013;13:176-81.
29. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. BMJ 1994;304:1088-91.
31. Lane DP, Anderson PM, Young RC, Serjant R, Bell J, Aitken JF. Body fat distribution and colorectal cancer: A case-control study in a US population. Cancer 2015;121:1071-8.
32. Vallet F. Diabetes mellitus and cancer of the digestive organs: An Italian population-based cohort study. J Diabetes Complications 2015;29:1056-61.
33. Lin HC, Hsu YT, Kachingwe BH, Hsu CY, Uang YS, Wang LH. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: A six-year population-based cohort study. J Clin Pharm Ther 2014;39:354-60.
34. Neumann A, Weill A, Ricordeau P, Poger JP, Alla F, Allemann H. Pioglitazone and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015;314:265-77.
35. Schleif A, Shic YC, Vekhter B, Bissosmette MB, Olopade OI, Polite BN. Metformin for primary colorectal cancer prevention in patients with diabetes: A case-control study in a US population. Cancer 2015;121:1071-8.
36. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution...
and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 2001;86:5366-71.

41. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375:408-18.

42. Weber MB, Oza-Frank R, Staimerz LR, Ali MK, Narayan KM. Type 2 diabetes in Asians: Prevalence, risk factors, and effectiveness of behavioral intervention at individual and population levels. Annu Rev Nutr 2012;32:417-39.

43. Kao CH, Sun LM, Chen PC, Lin MC, Liang JA, Muo CH, et al. A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients? Ann Oncol 2013;24:523-30.

44. Chiu CC, Huang CC, Chen YC, Chen TJ, Lin SJ, et al. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: A nationwide population-based study in Taiwan. Intern Med 2013;52:939-46.

45. Lai SW, Liao KF. Thiazolidinediones use and colorectal cancer risk. Diabetes Metab 2013;39:88.

46. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis. CMAJ 2012;184:E675-83.

47. Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis. Br J Clin Pharmacol 2014;78:258-73.

48. Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005;87:322-7.

49. Dominick MA, White MR, Sanderson TP, Van Vleet T, Cohen SM, Arnold LE, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muroglitazin, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 2006;34:903-20.

50. Nemenoff RA. Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus “off-target” effectors. J Thorac Oncol 2007;2:989-92.

51. Cornell S. Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. J Am Pharmacists Assoc 2017;57:261-5.

52. Balaji V, Seshiah V, Ashitalakshmi G, Ramanan SG, Janarthinakani M. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab 2014;18:425-7.

53. Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 2014;30:94-7.

54. Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: A propensity score matched cohort study. Br J Clin Pharmacol 2013;75:254-9.

55. Garber AJ, Abrahamson MJ, Barzilay JJ, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association Of Clinical Endocrinologists And American College Of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2017 Executive Summary. Endocr Pract 2017;23:207-38.

56. Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2013;22:2258-68.

57. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53:1838-45.

58. Erdmann E, Song E, Sphaneheimer R, van Troosteburg de Bruyn AR, Perez A. Observational follow-up of the PROactive study: A 6-year update. Diabetes Obesity Metab 2014;16:63-74.